XTX Topco Ltd Invests $207,000 in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

XTX Topco Ltd acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,254 shares of the specialty pharmaceutical company’s stock, valued at approximately $207,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ANIP. Dimensional Fund Advisors LP increased its stake in shares of ANI Pharmaceuticals by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock valued at $32,628,000 after buying an additional 33,359 shares during the period. Rubric Capital Management LP raised its stake in shares of ANI Pharmaceuticals by 32.8% during the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after acquiring an additional 277,989 shares during the last quarter. CastleKnight Management LP acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter worth $513,000. Ranger Investment Management L.P. grew its stake in shares of ANI Pharmaceuticals by 1.8% in the fourth quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock worth $23,965,000 after purchasing an additional 7,769 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in ANI Pharmaceuticals during the 4th quarter worth $132,000. Institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ANIP shares. Truist Financial reaffirmed a “hold” rating and issued a $60.00 price objective (down from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Finally, Raymond James upped their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $78.80.

ANI Pharmaceuticals Stock Up 0.8 %

ANI Pharmaceuticals stock opened at $58.78 on Monday. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $1.23 billion, a PE ratio of 36.74 and a beta of 0.71. The firm’s fifty day moving average is $60.64 and its 200 day moving average is $63.40. ANI Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. During the same quarter in the prior year, the firm earned $1.06 EPS. The business’s revenue was up 18.5% on a year-over-year basis. As a group, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Muthusamy Shanmugam sold 11,000 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $63.38, for a total transaction of $697,180.00. Following the completion of the sale, the chief operating officer now owns 671,620 shares in the company, valued at $42,567,275.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 26,007 shares of company stock worth $1,642,990. Corporate insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.